Heron Therapeutics, Inc. (HRTX)
Market Cap | 412.79M |
Revenue (ttm) | 132.10M |
Net Income (ttm) | -80.95M |
Shares Out | 150.65M |
EPS (ttm) | -0.59 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 7,493,670 |
Open | 3.450 |
Previous Close | 3.470 |
Day's Range | 2.710 - 3.470 |
52-Week Range | 0.500 - 3.930 |
Beta | 1.81 |
Analysts | Strong Buy |
Price Target | 6.00 (+118.98%) |
Earnings Date | Aug 12, 2024 |
About HRTX
Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiti... [Read more]
Financial Performance
In 2023, HRTX's revenue was $127.04 million, an increase of 17.99% compared to the previous year's $107.67 million. Losses were -$110.56 million, -39.26% less than in 2022.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for HRTX stock is "Strong Buy." The 12-month stock price forecast is $6.0, which is an increase of 118.98% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/i/c/press12-2506334.jpg)
Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")
-The U.S. Food and Drug Administration ("FDA") assigned a Prescription Drug User Fee Act ("PDUFA") goal date of September 23, 2024 SAN DIEGO , July 2, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Na...
![](https://cdn.snapi.dev/images/v1/v/b/press12-2451407.jpg)
Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")
SAN DIEGO, May 29, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the Prior Approval Supplement ("PA...
![](https://cdn.snapi.dev/images/v1/x/d/press15-2414425.jpg)
Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates
Net Product Sales of $34.7 million, which increased from $29.6 million for the same period in 2023. Net Loss Per Share $(0.02), which decreased from $(0.27) for the same period in 2023.
![](https://cdn.snapi.dev/images/v1/j/y/conf18-2387850.jpg)
Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
SAN DIEGO , April 24, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the company will host a conference call and live webc...
![](https://cdn.snapi.dev/images/v1/z/8/press11-2368146.jpg)
Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City
SAN DIEGO , April 11, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that it will host an Investor Day on Wednesday, May 15, 20...
![](https://cdn.snapi.dev/images/v1/d/u/press4-2347232.jpg)
Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
SAN DIEGO , March 28, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that Craig Collard, Chief Executive Officer of Heron, will...
![](https://cdn.snapi.dev/images/v1/k/0/press9-2320968.jpg)
Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates
2023 oncology care franchise revenue was $107.9 million, exceeding full-year 2023 guidance ZYNRELEF® achieved quarterly record of $5.6 million in Q4 Net Product Sales Ended 2023 with cash and cash equ...
![](https://cdn.snapi.dev/images/v1/u/a/conf15-2298327.jpg)
Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024
SAN DIEGO , Feb. 28, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the company will host a conference call and live webca...
![](https://cdn.snapi.dev/images/v1/e/a/press18-2241598.jpg)
Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures
– Expanded indication for ZYNRELEF now covers approximately 13 million procedures annually – SAN DIEGO , Jan. 23, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biote...
![](https://cdn.snapi.dev/images/v1/p/w/press2-2219485.jpg)
Heron Therapeutics Announces Partnership with CrossLink Life Sciences to Expand Promotional Effort for ZYNRELEF®, the First and Only Non-Opioid Dual Acting Local Anesthetic for Post-Operative Pain
SAN DIEGO , Jan. 7, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that it has entered into a five-year distributor partnership...
![](https://cdn.snapi.dev/images/v1/y/r/press13-2158015.jpg)
Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial Guidance
Heron is increasing full-year 2023 Net Product Sales guidance for the oncology care franchise to a range of $104 million to $106 million from a prior range of $99 million to $103 million We anticipate...
![](https://cdn.snapi.dev/images/v1/k/q/conf4-2145329.jpg)
Heron Therapeutics to Report Third Quarter 2023 Financial Results On Tuesday, November 14, 2023
SAN DIEGO , Nov. 7, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing ...
![](https://cdn.snapi.dev/images/v1/q/2/press17-2022403.jpg)
Heron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updates
Company is well capitalized after signing $50 million working capital credit facility and recent $30 million equity raise Favorable outcome at Markman hearing in pending CINVANTI® ANDA patent litigati...
![](https://cdn.snapi.dev/images/v1/m/j/conf9-2010570.jpg)
Heron Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023
SAN DIEGO , Aug. 7, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing ...
![](https://cdn.snapi.dev/images/v1/2/r/press10-1984282.jpg)
Heron Therapeutics Announces Cost Reduction Plan and Restructuring
- Expected overall cash savings of $75 million through 2025 - New executive management team in place SAN DIEGO , July 24, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-sta...
![](https://cdn.snapi.dev/images/v1/6/5/press8-1984263.jpg)
Heron Therapeutics Announces $30 Million Private Placement Financing
SAN DIEGO , July 24, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing...
![](https://cdn.snapi.dev/images/v1/o/b/press10-1946436.jpg)
Heron Therapeutics Announces Appointment of Ira Duarte as Chief Financial Officer
SAN DIEGO , June 23, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treat...
![](https://cdn.snapi.dev/images/v1/n/d/press10-1930134.jpg)
Heron Therapeutics Announces Appointment of William Forbes, Pharm.D. as Chief Development Officer
SAN DIEGO , June 12, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treat...
![](https://cdn.snapi.dev/images/v1/w/w/press7-1886215.jpg)
Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2023 and Highlights Recent Corporate Updates
Net Product Sales for First Quarter of 2023 Grew 26% to $29.6 million, Compared to First Quarter Net Product Sales in 2022.
![](https://cdn.snapi.dev/images/v1/b/u/conf2-1872916.jpg)
Heron Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023
SAN DIEGO , May 4, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatme...
![](https://cdn.snapi.dev/images/v1/6/7/press5-1845833.jpg)
Heron Therapeutics Announces Commercial Leadership Changes
SAN DIEGO , April 20, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron"), a commercial-stage biotechnology company focused on improving the lives of patients by developing and comm...
![](https://cdn.snapi.dev/images/v1/p/r/press19-1840458.jpg)
Heron Therapeutics Announces Presentation at 22nd Annual Needham Virtual Healthcare Conference
Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most importan...
![](https://cdn.snapi.dev/images/v1/c/x/press17-1823145.jpg)
Heron Therapeutics Announces New CEO and Board Chairman
Craig Collard Appointed CEO Adam Morgan Named Chairman of the Board SAN DIEGO , April 3, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ: HRTX) ("Heron" or the "Company"), a commercial-stage bio...
![](https://cdn.snapi.dev/images/v1/l/a/press11-1810583.jpg)
Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Highlights Recent Corporate Updates
- Annual Net Product Sales Across the Company Grew 25% to $107.7 million in 2022, Compared to Annual Net Product Sales in 2021 - - APONVIE™ Commercially Launched on March 6, 2023 - - ZYNRELEF ® Net P...
![](https://cdn.snapi.dev/images/v1/u/d/press14-1793757.jpg)
Heron Therapeutics Announces Centers for Medicare & Medicaid Services (CMS) Granted Pass-through Payment Status for APONVIE™, Effective April 1, 2023
SAN DIEGO , March 13, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class trea...